Table 3.
Summary of adverse event in the control and the hUC-MSC groups
| Group | All (n = 39) | Control (n = 20) | hUC-MSC (n = 19) | P valueA | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AE | Number (%) | Number (%) | Onset time post-treatment | Number (%) | Onset time post-treatment | |||||||
| 24 h | 7 days | 30 days | After 30 days | 24 h | 7 days | 30 days | After 30 days | |||||
| Upper respiratory infection | 24 (61.54%) | 14 (70.0%) | 0 | 1 | 3 | 10 | 10 (52.6%) | 0 | 2 | 2 | 6 | 0.333 |
| Diarrhea | 15 (38.46%) | 9 (45.0%) | 0 | 0 | 2 | 7 | 6 (31.6%) | 0 | 0 | 2 | 4 | 0.514 |
| Fever | 11 (28.21%) | 4 (20.0%) | 0 | 1 | 1 | 2 | 7 (36.8%) | 3 | 0 | 2 | 2 | 0.301 |
| Vomiting | 8 (20.51%) | 3 (15.0%) | 0 | 0 | 0 | 3 | 5 (26.3%) | 0 | 0 | 1 | 4 | 0.451 |
| Constipation | 4 (10.26%) | 3 (15.0%) | 0 | 0 | 1 | 2 | 1 (5.3%) | 0 | 0 | 0 | 1 | 0.605 |
Abbreviations: AE adverse event, hUC-MSC human umbilical cord-derived mesenchymal stem cell
AP value was calculated by Fisher’s exact test on the incidence between groups